长药控股涉财务造假 将依法启动退市程序

Group 1 - The China Securities Regulatory Commission (CSRC) has issued a prior administrative penalty notice against Changjiang Pharmaceutical Holdings Co., Ltd. (ST Changyao) for suspected false records in periodic reports and financial data [1] - *ST Changyao has inflated revenue and profits for three consecutive years, violating securities laws and regulations [1] - The CSRC plans to impose a fine of 10 million yuan on the company and a total of 31 million yuan on 14 responsible individuals, with the former general manager, Luo Ming, facing a lifetime ban from the securities market [1] Group 2 - *ST Changyao is potentially the 15th company this year facing mandatory delisting due to financial fraud, marking a record high for the number of companies reaching this threshold in a single year [1] - The increase in companies facing mandatory delisting is attributed to new regulations adjusting the delisting standards for financial fraud, as well as a strict regulatory stance against such practices [1] - The combination of administrative penalties, market bans, criminal referrals, delisting execution, and accountability for intermediaries is seen as a benchmark for the rule of law in the capital market, creating a closed-loop system for accountability [2]